Focus: Penumbra is a public medical device company specializing in minimally-invasive vascular and surgical devices for acute cardiovascular and neurovascular conditions. With $1.1B in FY2025 revenue, it is a established player in interventional device markets.
Profile data last refreshed 16h ago · AI intelligence enriched 1mo ago
Stable — net -2 jobs in 30d
40 added, 42 removed. Backfill posture.
Penumbra is ideal for commercial, supply chain, and operational career tracks in a high-growth medical device company, but less suitable for pharma scientists seeking early-stage drug discovery roles.
Help build intelligence for Penumbra
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Penumbra's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Could STORM-PE Data Change Penumbra (NASDAQ:PEN) Story? - Kalkine Media
Could STORM-PE Data Change Penumbra (NASDAQ:PEN) Story? Kalkine Media
8-K Filing: BOSTON SCIENTIFIC CORP (BSX) (CIK 0000885725) — EX-99.1
EX-99.1
Analysts Offer Insights on Healthcare Companies: Molina Healthcare (MOH), Vaxcyte (PCVX) and Penumbra (PEN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Molina Healthcare (MOH), Vaxcyte (PCVX) and Penumbra (PEN) The Globe and Mail
8-K Filing: DiaMedica Therapeutics Inc. (DMAC) (CIK 0001401040) — EXHIBIT 99.1
EXHIBIT 99.1
Boston Scientific unveils major restructuring, plots job cuts amid savings drive - Fierce Biotech
Boston Scientific unveils major restructuring, plots job cuts amid savings drive Fierce Biotech
3 Medical Device Stocks Giving Investors a Different Healthcare Play - Yahoo Finance
3 Medical Device Stocks Giving Investors a Different Healthcare Play Yahoo Finance
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo